Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Fineline Cube Dec 22, 2025
Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Fineline Cube Dec 22, 2025
Company Deals

JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development

Fineline Cube Dec 21, 2022

China-based JW Therapeutics Co., Ltd (HKG: 2126) has issued a stock exchange announcement revealing a...

Company Deals

Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm

Fineline Cube Dec 21, 2022

China-based Mabwell Bioscience (SHA: 688062) has announced the establishment of a licensing agreement with the...

Company Drug

Sirnaomics’ Lead Candidate STP707 Shows Promising Phase I Data

Fineline Cube Dec 21, 2022

Sino-US small interfering RNA (siRNA) specialist Sirnaomics (HKG: 2257) has revealed that its lead pipeline...

Company Drug

Kira Pharmaceuticals Gains NMPA and TGA Approvals for KP104 Phase II Study

Fineline Cube Dec 21, 2022

Sino-US biotech Kira Pharmaceuticals has announced receiving approvals from China’s National Medical Products Administration (NMPA)...

Company Deals

TowardPi Raises RMB 300 Million in Series C Financing Round

Fineline Cube Dec 20, 2022

China-based ophthalmology device maker TowardPi (Beijing) Medical Technology Ltd has reportedly raised close to RMB...

Company Drug

Aosaikang Receives FDA Approval for ASKG915 Clinical Trial

Fineline Cube Dec 20, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its...

Company Deals

Pfizer Exercises Option for Sisunatovir Rights with LianBio

Fineline Cube Dec 20, 2022

US major Pfizer Inc. (NYSE: PFE) has agreed with China-based LianBio (OTCMKTS: LIANY) to exercise...

Company Deals

Fosun Pharma Registers Comirnaty Vaccines in Hong Kong

Fineline Cube Dec 20, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced that Comirnaty (BNT162b2) and Comirnaty bivalent...

Company Deals

XtalPi Partners with Singapore’s EDDC to Develop Lung Cancer Treatments

Fineline Cube Dec 20, 2022

Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with the Experimental Drug...

Deals

Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services

Fineline Cube Dec 20, 2022

Hong Kong-based Prenetics Global Ltd (NASDAQ: PRE) has announced the acquisition of a majority stake...

Company Drug

CStone’s Sugemalimab MAA Accepted by UK MHRA for NSCLC Treatment

Fineline Cube Dec 20, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has announced that the Medicines and Healthcare products Regulatory Agency...

Company Drug

Ascletis Pharma Receives USPTO Notice for ASC10 Patent

Fineline Cube Dec 20, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the Notice of Issuance from the...

Company Drug

HutchMed Initiates Rolling NDA Submission for Elunate to US FDA

Fineline Cube Dec 20, 2022

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the initiation of a rolling...

Legal / IP Policy / Regulatory

PCAOB Report Signals Relief for US-Listed Chinese Biotechs

Fineline Cube Dec 20, 2022

A report issued last week by the US Public Company Accounting Oversight Board (PCAOB) indicated...

Company Deals

Luye Pharma’s Shandong Boan Biotechnology IPOs on Hong Kong Stock Exchange

Fineline Cube Dec 19, 2022

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd has officially...

Company Drug

Simcere Pharmaceutical Completes Enrollment for SIM0417 COVID-19 Drug Trial

Fineline Cube Dec 19, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the completion of enrollment of 1,208 patients...

Company Drug

Neurophth’s NFS-02 Gene Therapy Gets FDA IND Approval for LHON Treatment

Fineline Cube Dec 19, 2022

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced obtaining Investigational New Drug (IND) approval...

Company Drug

TG ImmunoPharma Gains FDA Approval for Phase I Study of Anti-PVRIG Antibody

Fineline Cube Dec 19, 2022

China-based TG ImmunoPharma Co., Ltd has announced receiving the go-ahead from the US FDA to...

Company Deals Drug

Adagene Initiates International Study for ADG126 in Hepatocellular Carcinoma

Fineline Cube Dec 19, 2022

China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has...

Company Drug

Jiangsu Recbio’s Herpes Zoster Vaccine REC610 Gets Clinical Trial Approval in Philippines

Fineline Cube Dec 19, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced receiving clinical trial...

Posts pagination

1 … 519 520 521 … 600

Recent updates

  • Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial
  • Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis
  • MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED
  • Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal
  • Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.